Effect of long-term GHRH and somatostatin administration on GH release and body weight in prepubertal female rats.

Pérez-Romero A, Rol de Lama MA, Ariznavarreta C, Tresguerres JA

Journal of physiology and biochemistry1 Dec 1999Cited by 4 (Europe PMC)

PMID10731083DOI10.1007/bf03655584PepBankPUB-10731083

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, GHRH at the highest daily dose significantly increased body weight.
In plain wordsIn young female rats, the highest daily GHRH dose increased body weight.
Peptide
Sermorelin
Outcome
IncreaseBody weight with high-dose GHRH (experiment 1)
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Body weight · Metabolic and weight
Studied dose
1200 microg/day · subcutaneous · 19 daysAs given in this study (rat).
Source sentences
Summary
In experiment 1, body weight was significantly increased when GHRH was administered at the highest daily dosage (1200 microg/day)
2 context sentences(design, population, supporting numbers)
Summary · context
In experiment 1, the rats received sc injections of GHRH and cyclic natural SS for 19 days.
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108301
02AnimalAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, GHRH at the highest daily dose was accompanied by a slight increase in pituitary GH content.
In plain wordsIn young female rats, the highest daily GHRH dose came with a slight rise in growth hormone stored in the pituitary gland.
Peptide
Sermorelin
Outcome
IncreasePituitary GH content with high-dose GHRH (experiment 1)
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1200 microg/day · subcutaneous · 19 daysAs given in this study (rat).
Source sentences
Summary
accompanied by an slight increment in pituitary GH content.
2 context sentences(design, population, supporting numbers)
Summary · context
In experiment 1, the rats received sc injections of GHRH and cyclic natural SS for 19 days.
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108302
03AnimalAnimal study (in vivo)Mechanism
In prepubertal female rats, hypothalamic somatostatin concentrations decreased when GHRH was given alone.
In plain wordsIn young female rats, GHRH given alone lowered somatostatin levels in the hypothalamus.
Peptide
Sermorelin
Outcome
DecreaseHypothalamic somatostatin with GHRH alone
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (rat).
Source sentences
Summary
Hypothalamic SS concentrations decreased when GHRH or SS were administered alone
1 context sentence(design, population, supporting numbers)
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108303
04AnimalAnimal study (in vivo)Mechanism
In prepubertal female rats, the combined treatment with GHRH and somatostatin did not modify hypothalamic somatostatin concentrations.
In plain wordsIn young female rats, GHRH given together with somatostatin did not change somatostatin levels in the hypothalamus.
Peptide
Sermorelin
Outcome
No significant changeHypothalamic somatostatin with GHRH plus somatostatin
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (rat).
Source sentences
Summary
whereas the combined treatment with both peptides did not modify this parameter
1 context sentence(design, population, supporting numbers)
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108304
05AnimalAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, continuous GHRH infusion increased plasma GH levels.
In plain wordsIn young female rats, a steady GHRH infusion raised growth hormone levels in the blood.
Peptide
Sermorelin
Outcome
IncreasePlasma GH with continuous GHRH infusion (experiment 2)
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · slow-release pellet · 21 daysAs given in this study (rat).
Source sentences
Summary
In experiment 2, the continuous infusion of GHRH increased plasma GH levels
2 context sentences(design, population, supporting numbers)
Summary · context
In the second study, female rats were continuously treated during 21 days with GHRH, using a slow release pellet, alone or combined with one daily injection of long acting SS (octreotide).
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108305
06AnimalAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, continuous GHRH infusion tended to enhance pituitary GH content; this was a trend.
In plain wordsIn young female rats, a steady GHRH infusion tended to raise growth hormone stored in the pituitary gland.
Peptide
Sermorelin
Outcome
No significant changePituitary GH content with continuous GHRH infusion (experiment 2)
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · slow-release pellet · 21 daysAs given in this study (rat).
Source sentences
Summary
and tended to enhance pituitary GH content.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second study, female rats were continuously treated during 21 days with GHRH, using a slow release pellet, alone or combined with one daily injection of long acting SS (octreotide).
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108306
07AnimalAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, the GHRH effect was not effective enough to increase body weight.
In plain wordsIn young female rats, a steady GHRH infusion did not increase body weight.
Peptide
Sermorelin
Outcome
No significant changeBody weight with continuous GHRH infusion (experiment 2)
Study
ratn: not reported in source
Prepubertal female rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · slow-release pellet · 21 daysAs given in this study (rat).
Source sentences
Summary
Nevertheless, GHRH effect was not effective enough to increase body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second study, female rats were continuously treated during 21 days with GHRH, using a slow release pellet, alone or combined with one daily injection of long acting SS (octreotide).
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
Report a problemFND-1073108307

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

08AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Efficacy outcome
In prepubertal female rats, adding one daily injection of long acting somatostatin (octreotide) abolished the GHRH effects on the pituitary gland.
In plain wordsIn young female rats, adding a daily octreotide injection removed the effects of GHRH on the pituitary gland compared with GHRH alone.
Peptide
Sermorelin
Outcome
No significant changePituitary effects of GHRH with daily octreotide (experiment 2)
Study
ratn: not reported in source
Prepubertal female rats
Comparator
GHRH alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
By adding one daily injection of SS both GHRH effects on the pituitary gland were abolished.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second study, female rats were continuously treated during 21 days with GHRH, using a slow release pellet, alone or combined with one daily injection of long acting SS (octreotide).
Summary · context
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS).
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-1073108308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.